Proactiveinvestors Australia Allergy Therapeutics PLC https://www.proactiveinvestors.com.au Proactiveinvestors Australia Allergy Therapeutics PLC RSS feed en Thu, 14 Nov 2019 20:33:52 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Allergy Therapeutics: Profitable, growing and with product pipeline not to be sneezed at https://www.proactiveinvestors.com.au/companies/news/903472/allergy-therapeutics-profitable-growing-and-with-product-pipeline-not-to-be-sneezed-at-903472.html Fri, 25 Oct 2019 05:46:00 +1100 https://www.proactiveinvestors.com.au/companies/news/903472/allergy-therapeutics-profitable-growing-and-with-product-pipeline-not-to-be-sneezed-at-903472.html FTSE 100 closes almost flat as US stocks rally on Trump trade war optimism https://www.proactiveinvestors.com.au/companies/news/903410/ftse-100-closes-almost-flat-as-us-stocks-rally-on-trump-trade-war-optimism-903410.html Wed, 25 Sep 2019 16:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903410/ftse-100-closes-almost-flat-as-us-stocks-rally-on-trump-trade-war-optimism-903410.html Allergy Therapeutics confident on the coming year as it reports 8% boost to revenues https://www.proactiveinvestors.com.au/companies/news/903429/allergy-therapeutics-confident-on-the-coming-year-as-it-reports-8-boost-to-revenues-903429.html Wed, 25 Sep 2019 07:51:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903429/allergy-therapeutics-confident-on-the-coming-year-as-it-reports-8-boost-to-revenues-903429.html Allergy Therapeutics enjoys a strong and profitable year https://www.proactiveinvestors.com.au/companies/news/903412/allergy-therapeutics-enjoys-a-strong-and-profitable-year-903412.html Wed, 25 Sep 2019 06:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903412/allergy-therapeutics-enjoys-a-strong-and-profitable-year-903412.html Allergy Therapeutics continues to trade ahead of expectations as it makes market share gains https://www.proactiveinvestors.com.au/companies/news/223720/allergy-therapeutics-continues-to-trade-ahead-of-expectations-as-it-makes-market-share-gains-223720.html Thu, 11 Jul 2019 10:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/223720/allergy-therapeutics-continues-to-trade-ahead-of-expectations-as-it-makes-market-share-gains-223720.html Allergy Therapeutics expects earnings to come in ahead of market expectations https://www.proactiveinvestors.com.au/companies/news/314057/allergy-therapeutics-expects-earnings-to-come-in-ahead-of-market-expectations-14057.html Thu, 11 Jul 2019 07:25:00 +1000 https://www.proactiveinvestors.com.au/companies/news/314057/allergy-therapeutics-expects-earnings-to-come-in-ahead-of-market-expectations-14057.html Allergy Therapeutics jumps as it lifts profit forecasts after multi-million-dollar legal victory https://www.proactiveinvestors.com.au/companies/news/222926/allergy-therapeutics-jumps-as-it-lifts-profit-forecasts-after-multi-million-dollar-legal-victory-222926.html Thu, 27 Jun 2019 08:05:00 +1000 https://www.proactiveinvestors.com.au/companies/news/222926/allergy-therapeutics-jumps-as-it-lifts-profit-forecasts-after-multi-million-dollar-legal-victory-222926.html Allergy Therapeutics reports positive results from early-stage study of dust mite jab https://www.proactiveinvestors.com.au/companies/news/220568/allergy-therapeutics-reports-positive-results-from-early-stage-study-of-dust-mite-jab-220568.html Mon, 20 May 2019 13:05:00 +1000 https://www.proactiveinvestors.com.au/companies/news/220568/allergy-therapeutics-reports-positive-results-from-early-stage-study-of-dust-mite-jab-220568.html Allergy Therapeutics thinks its adjuvant system could be used in fight against cancer https://www.proactiveinvestors.com.au/companies/news/219779/allergy-therapeutics-thinks-its-adjuvant-system-could-be-used-in-fight-against-cancer-219779.html Tue, 07 May 2019 08:05:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219779/allergy-therapeutics-thinks-its-adjuvant-system-could-be-used-in-fight-against-cancer-219779.html Allergy Therapeutics gets regulatory green light for phase III grass pollen trial https://www.proactiveinvestors.com.au/companies/news/219075/allergy-therapeutics-gets-regulatory-green-light-for-phase-iii-grass-pollen-trial-219075.html Thu, 25 Apr 2019 06:54:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219075/allergy-therapeutics-gets-regulatory-green-light-for-phase-iii-grass-pollen-trial-219075.html Allergy Therapeutics surprised by the results of PQ Birch jab trial https://www.proactiveinvestors.com.au/companies/news/216609/allergy-therapeutics-surprised-by-the-results-of-pq-birch-jab-trial-216609.html Mon, 18 Mar 2019 07:26:00 +1100 https://www.proactiveinvestors.com.au/companies/news/216609/allergy-therapeutics-surprised-by-the-results-of-pq-birch-jab-trial-216609.html Allergy Therapeutics sees first-half sales, profits jump ahead of “pivotal” year https://www.proactiveinvestors.com.au/companies/news/215888/allergy-therapeutics-sees-first-half-sales-profits-jump-ahead-of-pivotal-year-215888.html Wed, 06 Mar 2019 12:10:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215888/allergy-therapeutics-sees-first-half-sales-profits-jump-ahead-of-pivotal-year-215888.html Allergy Therapeutics celebrating 20 years of growth and innovation https://www.proactiveinvestors.com.au/companies/news/312481/allergy-therapeutics-celebrating-20-years-of-growth-and-innovation-12481.html Wed, 06 Mar 2019 08:38:00 +1100 https://www.proactiveinvestors.com.au/companies/news/312481/allergy-therapeutics-celebrating-20-years-of-growth-and-innovation-12481.html Allergy Therapeutics higher as revenues rise 10.6%, cash reserves grow https://www.proactiveinvestors.com.au/companies/news/212664/allergy-therapeutics-higher-as-revenues-rise-106-cash-reserves-grow-212664.html Wed, 16 Jan 2019 12:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/212664/allergy-therapeutics-higher-as-revenues-rise-106-cash-reserves-grow-212664.html Allergy Therapeutics says revenues “up strongly on prior year” in update ahead of AGM https://www.proactiveinvestors.com.au/companies/news/209999/allergy-therapeutics-says-revenues-up-strongly-on-prior-year-in-update-ahead-of-agm-209999.html Tue, 27 Nov 2018 14:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/209999/allergy-therapeutics-says-revenues-up-strongly-on-prior-year-in-update-ahead-of-agm-209999.html Allergy Therapeutics pleased with the current momentum in the business https://www.proactiveinvestors.com.au/companies/news/205733/allergy-therapeutics-pleased-with-the-current-momentum-in-the-business-205733.html Thu, 27 Sep 2018 09:28:00 +1000 https://www.proactiveinvestors.com.au/companies/news/205733/allergy-therapeutics-pleased-with-the-current-momentum-in-the-business-205733.html Allergy Therapeutics outperforming the market "significantly" in latest financial year https://www.proactiveinvestors.com.au/companies/news/310614/allergy-therapeutics-outperforming-the-market-significantly-in-latest-financial-year-10614.html Wed, 26 Sep 2018 09:08:00 +1000 https://www.proactiveinvestors.com.au/companies/news/310614/allergy-therapeutics-outperforming-the-market-significantly-in-latest-financial-year-10614.html Allergy Therapeutics raises £10.6mln to fund expansion of late-stage PQ Grass study https://www.proactiveinvestors.com.au/companies/news/201111/allergy-therapeutics-raises-106mln-to-fund-expansion-of-late-stage-pq-grass-study-201111.html Thu, 19 Jul 2018 09:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/201111/allergy-therapeutics-raises-106mln-to-fund-expansion-of-late-stage-pq-grass-study-201111.html Allergy Therapeutics full-year revenues to rise once again despite “unusually weak” pollen season https://www.proactiveinvestors.com.au/companies/news/200649/allergy-therapeutics-full-year-revenues-to-rise-once-again-despite-unusually-weak-pollen-season-200649.html Thu, 12 Jul 2018 06:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/200649/allergy-therapeutics-full-year-revenues-to-rise-once-again-despite-unusually-weak-pollen-season-200649.html Allergy Therapeutics announces publication of positive data of Pollinex Quattro Grass vaccines https://www.proactiveinvestors.com.au/companies/news/199455/allergy-therapeutics-announces-publication-of-positive-data-of-pollinex-quattro-grass-vaccines-199455.html Mon, 25 Jun 2018 06:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/199455/allergy-therapeutics-announces-publication-of-positive-data-of-pollinex-quattro-grass-vaccines-199455.html Allergy Therapeutics announces positive new clinic data with house-dust mite immunotherapy https://www.proactiveinvestors.com.au/companies/news/197788/allergy-therapeutics-announces-positive-new-clinic-data-with-house-dust-mite-immunotherapy-197788.html Tue, 29 May 2018 06:32:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197788/allergy-therapeutics-announces-positive-new-clinic-data-with-house-dust-mite-immunotherapy-197788.html Allergy Therapeutics readies grass pollen treatment for Phase III trial after “extremely positive” mid-stage results https://www.proactiveinvestors.com.au/companies/news/197344/allergy-therapeutics-readies-grass-pollen-treatment-for-phase-iii-trial-after-extremely-positive-mid-stage-results-197344.html Mon, 21 May 2018 09:54:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197344/allergy-therapeutics-readies-grass-pollen-treatment-for-phase-iii-trial-after-extremely-positive-mid-stage-results-197344.html Allergy Therapeutics on track for phase III grass pollen trial in 2019 https://www.proactiveinvestors.com.au/companies/news/309336/allergy-therapeutics-on-track-for-phase-iii-grass-pollen-trial-in-2019-9336.html Mon, 21 May 2018 07:59:00 +1000 https://www.proactiveinvestors.com.au/companies/news/309336/allergy-therapeutics-on-track-for-phase-iii-grass-pollen-trial-in-2019-9336.html Allergy Therapeutics highlights benefits of adjuvant technology in new paper https://www.proactiveinvestors.com.au/companies/news/196896/allergy-therapeutics-highlights-benefits-of-adjuvant-technology-in-new-paper-196896.html Mon, 14 May 2018 07:27:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196896/allergy-therapeutics-highlights-benefits-of-adjuvant-technology-in-new-paper-196896.html 'Pivotal' year ahead for Allergy Therapeutics with key trial readouts https://www.proactiveinvestors.com.au/companies/news/308851/-pivotal-year-ahead-for-allergy-therapeutics-with-key-trial-readouts-8851.html Wed, 07 Mar 2018 08:56:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308851/-pivotal-year-ahead-for-allergy-therapeutics-with-key-trial-readouts-8851.html Allergy Therapeutics grows market share ahead of key trial results https://www.proactiveinvestors.com.au/companies/news/192741/allergy-therapeutics-grows-market-share-ahead-of-key-trial-results-192741.html Wed, 07 Mar 2018 07:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/192741/allergy-therapeutics-grows-market-share-ahead-of-key-trial-results-192741.html Allergy Therapeutics teams up with German manufacturer to scale up production of peanut allergy vaccine https://www.proactiveinvestors.com.au/companies/news/192329/allergy-therapeutics-teams-up-with-german-manufacturer-to-scale-up-production-of-peanut-allergy-vaccine-192329.html Wed, 28 Feb 2018 08:06:00 +1100 https://www.proactiveinvestors.com.au/companies/news/192329/allergy-therapeutics-teams-up-with-german-manufacturer-to-scale-up-production-of-peanut-allergy-vaccine-192329.html Allergy Therapeutics' grass pollen study running ahead of schedule https://www.proactiveinvestors.com.au/companies/news/191486/allergy-therapeutics-grass-pollen-study-running-ahead-of-schedule-191486.html Mon, 12 Feb 2018 13:39:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191486/allergy-therapeutics-grass-pollen-study-running-ahead-of-schedule-191486.html Allergy Therapeutics expects first-half revenue rise; continues to take market share from rivals https://www.proactiveinvestors.com.au/companies/news/190883/allergy-therapeutics-expects-first-half-revenue-rise-continues-to-take-market-share-from-rivals-190883.html Wed, 31 Jan 2018 07:52:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190883/allergy-therapeutics-expects-first-half-revenue-rise-continues-to-take-market-share-from-rivals-190883.html Allergy Therapeutics completes recruitment for phase III birch pollen trial https://www.proactiveinvestors.com.au/companies/news/189703/allergy-therapeutics-completes-recruitment-for-phase-iii-birch-pollen-trial-189703.html Tue, 09 Jan 2018 07:29:00 +1100 https://www.proactiveinvestors.com.au/companies/news/189703/allergy-therapeutics-completes-recruitment-for-phase-iii-birch-pollen-trial-189703.html Allergy Therapeutics teams up with Ergomed to take its anti-allergy tablets through the clinic https://www.proactiveinvestors.com.au/companies/news/188639/allergy-therapeutics-teams-up-with-ergomed-to-take-its-anti-allergy-tablets-through-the-clinic-188639.html Tue, 12 Dec 2017 08:21:00 +1100 https://www.proactiveinvestors.com.au/companies/news/188639/allergy-therapeutics-teams-up-with-ergomed-to-take-its-anti-allergy-tablets-through-the-clinic-188639.html Allergy Therapeutics - strong financial showing, solid cash position, progress in the clinic https://www.proactiveinvestors.com.au/companies/news/184731/allergy-therapeutics-strong-financial-showing-solid-cash-position-progress-in-the-clinic-184731.html Fri, 20 Oct 2017 09:08:00 +1100 https://www.proactiveinvestors.com.au/companies/news/184731/allergy-therapeutics-strong-financial-showing-solid-cash-position-progress-in-the-clinic-184731.html Allergy Therapeutics starts dosing for injected hay fever vaccine trial https://www.proactiveinvestors.com.au/companies/news/185854/allergy-therapeutics-starts-dosing-for-injected-hay-fever-vaccine-trial-185854.html Thu, 19 Oct 2017 07:11:00 +1100 https://www.proactiveinvestors.com.au/companies/news/185854/allergy-therapeutics-starts-dosing-for-injected-hay-fever-vaccine-trial-185854.html Allergy Therapeutics preparing the ground for big opportunities in the US https://www.proactiveinvestors.com.au/companies/news/308152/allergy-therapeutics-preparing-the-ground-for-big-opportunities-in-the-us-8152.html Thu, 28 Sep 2017 07:28:00 +1000 https://www.proactiveinvestors.com.au/companies/news/308152/allergy-therapeutics-preparing-the-ground-for-big-opportunities-in-the-us-8152.html Allergy Therapeutics set to begin phase II trial of PQ Grass hay fever treatment “imminently” https://www.proactiveinvestors.com.au/companies/news/184124/allergy-therapeutics-set-to-begin-phase-ii-trial-of-pq-grass-hay-fever-treatment-imminently-184124.html Mon, 18 Sep 2017 14:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/184124/allergy-therapeutics-set-to-begin-phase-ii-trial-of-pq-grass-hay-fever-treatment-imminently-184124.html Allergy Therapeutics strengthens clinical research team with senior appointments https://www.proactiveinvestors.com.au/companies/news/183722/allergy-therapeutics-strengthens-clinical-research-team-with-senior-appointments-183722.html Mon, 11 Sep 2017 06:24:00 +1000 https://www.proactiveinvestors.com.au/companies/news/183722/allergy-therapeutics-strengthens-clinical-research-team-with-senior-appointments-183722.html Allergy Therapeutics revenues rise as hay fever portfolio cleans up https://www.proactiveinvestors.com.au/companies/news/128137/allergy-therapeutics-revenues-rise-as-hay-fever-portfolio-cleans-up-128137.html Tue, 18 Jul 2017 09:37:00 +1000 https://www.proactiveinvestors.com.au/companies/news/128137/allergy-therapeutics-revenues-rise-as-hay-fever-portfolio-cleans-up-128137.html Allergy Therapeutics sales soar as market share in Europe rises https://www.proactiveinvestors.com.au/companies/news/181043/allergy-therapeutics-sales-soar-as-market-share-in-europe-rises-181043.html Tue, 18 Jul 2017 07:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/181043/allergy-therapeutics-sales-soar-as-market-share-in-europe-rises-181043.html Allergy Therapeutics publishes pre-clinical data on malaria and flu vaccines https://www.proactiveinvestors.com.au/companies/news/180447/allergy-therapeutics-publishes-pre-clinical-data-on-malaria-and-flu-vaccines-180447.html Thu, 06 Jul 2017 07:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/180447/allergy-therapeutics-publishes-pre-clinical-data-on-malaria-and-flu-vaccines-180447.html Allergy Therapeutics tipped to rise to 32p in coming months https://www.proactiveinvestors.com.au/companies/news/307190/allergy-therapeutics-tipped-to-rise-to-32p-in-coming-months-7190.html Thu, 30 Mar 2017 11:03:00 +1100 https://www.proactiveinvestors.com.au/companies/news/307190/allergy-therapeutics-tipped-to-rise-to-32p-in-coming-months-7190.html Allergy Therapeutics 'confident in the future of the business' https://www.proactiveinvestors.com.au/companies/news/307217/allergy-therapeutics-confident-in-the-future-of-the-business--7217.html Wed, 29 Mar 2017 14:27:00 +1100 https://www.proactiveinvestors.com.au/companies/news/307217/allergy-therapeutics-confident-in-the-future-of-the-business--7217.html Allergy Therapeutics confident of further growth https://www.proactiveinvestors.com.au/companies/news/175588/allergy-therapeutics-confident-of-further-growth-175588.html Wed, 29 Mar 2017 07:17:00 +1100 https://www.proactiveinvestors.com.au/companies/news/175588/allergy-therapeutics-confident-of-further-growth-175588.html Allergy Therapeutics recruits first patients to its phase III birch trial https://www.proactiveinvestors.com.au/companies/news/174897/allergy-therapeutics-recruits-first-patients-to-its-phase-iii-birch-trial-174897.html Thu, 16 Mar 2017 07:43:00 +1100 https://www.proactiveinvestors.com.au/companies/news/174897/allergy-therapeutics-recruits-first-patients-to-its-phase-iii-birch-trial-174897.html Allergy Therapeutics shares tipped to rise to 32p https://www.proactiveinvestors.com.au/companies/news/306955/allergy-therapeutics-shares-tipped-to-rise-to-32p-6955.html Tue, 21 Feb 2017 10:53:00 +1100 https://www.proactiveinvestors.com.au/companies/news/306955/allergy-therapeutics-shares-tipped-to-rise-to-32p-6955.html Allergy Therapeutics launches phase I trial of dust mite inoculation https://www.proactiveinvestors.com.au/companies/news/173113/allergy-therapeutics-launches-phase-i-trial-of-dust-mite-inoculation-173113.html Tue, 14 Feb 2017 15:05:00 +1100 https://www.proactiveinvestors.com.au/companies/news/173113/allergy-therapeutics-launches-phase-i-trial-of-dust-mite-inoculation-173113.html Allergy Therapeutics' Murray Skinner talks up 'huge market opportunities' for dust mite treatment https://www.proactiveinvestors.com.au/companies/news/306911/allergy-therapeutics-murray-skinner-talks-up-huge-market-opportunities-for-dust-mite-treatment-6911.html Tue, 14 Feb 2017 14:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/306911/allergy-therapeutics-murray-skinner-talks-up-huge-market-opportunities-for-dust-mite-treatment-6911.html Allergy Therapeutics unveils new non-executive director https://www.proactiveinvestors.com.au/companies/news/172846/allergy-therapeutics-unveils-new-non-executive-director-172846.html Wed, 08 Feb 2017 08:31:00 +1100 https://www.proactiveinvestors.com.au/companies/news/172846/allergy-therapeutics-unveils-new-non-executive-director-172846.html Allergy Therapeutics peanut allergy vaccine to move into phase I trials after pre-clinical success https://www.proactiveinvestors.com.au/companies/news/172471/allergy-therapeutics-peanut-allergy-vaccine-to-move-into-phase-i-trials-after-pre-clinical-success-172471.html Wed, 01 Feb 2017 15:26:00 +1100 https://www.proactiveinvestors.com.au/companies/news/172471/allergy-therapeutics-peanut-allergy-vaccine-to-move-into-phase-i-trials-after-pre-clinical-success-172471.html Allergy Therapeutics hails progression of peanut allergy vaccine https://www.proactiveinvestors.com.au/companies/news/306831/allergy-therapeutics-hails-progression-of-peanut-allergy-vaccine-6831.html Wed, 01 Feb 2017 12:40:00 +1100 https://www.proactiveinvestors.com.au/companies/news/306831/allergy-therapeutics-hails-progression-of-peanut-allergy-vaccine-6831.html Not to be sneezed at - Allergy Therapeutics revenues up 18% https://www.proactiveinvestors.com.au/companies/news/171855/not-to-be-sneezed-at-allergy-therapeutics-revenues-up-18-171855.html Thu, 19 Jan 2017 07:42:00 +1100 https://www.proactiveinvestors.com.au/companies/news/171855/not-to-be-sneezed-at-allergy-therapeutics-revenues-up-18-171855.html Broker 'nuts' about Allergy Therapeutics; reckons stock could double in value https://www.proactiveinvestors.com.au/companies/news/171252/broker-nuts-about-allergy-therapeutics-reckons-stock-could-double-in-value-171252.html Fri, 06 Jan 2017 08:34:00 +1100 https://www.proactiveinvestors.com.au/companies/news/171252/broker-nuts-about-allergy-therapeutics-reckons-stock-could-double-in-value-171252.html Allergy Therapeutics gets European patent for Microcrystalline Tyrosine technology https://www.proactiveinvestors.com.au/companies/news/168395/allergy-therapeutics-gets-european-patent-for-microcrystalline-tyrosine-technology-168395.html Wed, 02 Nov 2016 08:12:00 +1100 https://www.proactiveinvestors.com.au/companies/news/168395/allergy-therapeutics-gets-european-patent-for-microcrystalline-tyrosine-technology-168395.html Allergy Therapeutics' malaria boost https://www.proactiveinvestors.com.au/companies/news/167136/allergy-therapeutics-malaria-boost-167136.html Mon, 10 Oct 2016 06:53:00 +1100 https://www.proactiveinvestors.com.au/companies/news/167136/allergy-therapeutics-malaria-boost-167136.html Focus remains US, says expanding Allergy Therapeutics https://www.proactiveinvestors.com.au/companies/news/306058/focus-remains-us-says-expanding-allergy-therapeutics-6058.html Wed, 28 Sep 2016 09:02:00 +1000 https://www.proactiveinvestors.com.au/companies/news/306058/focus-remains-us-says-expanding-allergy-therapeutics-6058.html Allergy Therapeutics half yearly revenues grow amid market turmoil https://www.proactiveinvestors.com.au/companies/news/166446/allergy-therapeutics-half-yearly-revenues-grow-amid-market-turmoil-166446.html Mon, 26 Sep 2016 08:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/166446/allergy-therapeutics-half-yearly-revenues-grow-amid-market-turmoil-166446.html Forex headwinds could turn into tailwinds at Allergy Therapeutics https://www.proactiveinvestors.com.au/companies/news/305287/forex-headwinds-could-turn-into-tailwinds-at-allergy-therapeutics-5287.html Fri, 15 Jul 2016 11:02:00 +1000 https://www.proactiveinvestors.com.au/companies/news/305287/forex-headwinds-could-turn-into-tailwinds-at-allergy-therapeutics-5287.html Allergy Therapeutics upbeat after raising annual revenue forecasts https://www.proactiveinvestors.com.au/companies/news/305279/allergy-therapeutics-upbeat-after-raising-annual-revenue-forecasts-5279.html Thu, 14 Jul 2016 08:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/305279/allergy-therapeutics-upbeat-after-raising-annual-revenue-forecasts-5279.html Allergy Therapeutics sees "statistically significant" improvement one year on https://www.proactiveinvestors.com.au/companies/news/127997/allergy-therapeutics-sees-statistically-significant-improvement-one-year-on-127997.html Fri, 08 Jul 2016 06:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/127997/allergy-therapeutics-sees-statistically-significant-improvement-one-year-on-127997.html Allergy Therapeutics to take different approach to grass pollen jab https://www.proactiveinvestors.com.au/companies/news/127522/allergy-therapeutics-to-take-different-approach-to-grass-pollen-jab-127522.html Mon, 27 Jun 2016 06:53:00 +1000 https://www.proactiveinvestors.com.au/companies/news/127522/allergy-therapeutics-to-take-different-approach-to-grass-pollen-jab-127522.html Allergy Therapeutics appoints ex- Skyepharma man as FD https://www.proactiveinvestors.com.au/companies/news/126980/allergy-therapeutics-appoints-ex-skyepharma-man-as-fd-126980.html Fri, 10 Jun 2016 13:01:00 +1000 https://www.proactiveinvestors.com.au/companies/news/126980/allergy-therapeutics-appoints-ex-skyepharma-man-as-fd-126980.html Allergy Therapeutics boss excited by PQBirch204 Phase II data https://www.proactiveinvestors.com.au/companies/news/305005/allergy-therapeutics-boss-excited-by-pqbirch204-phase-ii-data-5005.html Mon, 09 May 2016 13:25:00 +1000 https://www.proactiveinvestors.com.au/companies/news/305005/allergy-therapeutics-boss-excited-by-pqbirch204-phase-ii-data-5005.html Allergy Therapeutics' results not to be sniffed at https://www.proactiveinvestors.com.au/companies/news/125675/allergy-therapeutics-results-not-to-be-sniffed-at-125675.html Mon, 09 May 2016 11:33:00 +1000 https://www.proactiveinvestors.com.au/companies/news/125675/allergy-therapeutics-results-not-to-be-sniffed-at-125675.html Allergy Therapeutics PLC FD off to new pastures https://www.proactiveinvestors.com.au/companies/news/123796/allergy-therapeutics-plc-fd-off-to-new-pastures-123796.html Thu, 17 Mar 2016 09:15:00 +1100 https://www.proactiveinvestors.com.au/companies/news/123796/allergy-therapeutics-plc-fd-off-to-new-pastures-123796.html Allergy Therapeutics says double-digit revenue growth is sustainable https://www.proactiveinvestors.com.au/companies/news/304742/allergy-therapeutics-says-double-digit-revenue-growth-is-sustainable-4742.html Tue, 08 Mar 2016 15:04:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304742/allergy-therapeutics-says-double-digit-revenue-growth-is-sustainable-4742.html Allergy Therapeutics PLC outperforming the market https://www.proactiveinvestors.com.au/companies/news/123418/allergy-therapeutics-plc-outperforming-the-market-123418.html Tue, 08 Mar 2016 13:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/123418/allergy-therapeutics-plc-outperforming-the-market-123418.html Allergy Therapeutics PLC grows in Europe and targets US https://www.proactiveinvestors.com.au/companies/news/123395/allergy-therapeutics-plc-grows-in-europe-and-targets-us-123395.html Tue, 08 Mar 2016 07:35:00 +1100 https://www.proactiveinvestors.com.au/companies/news/123395/allergy-therapeutics-plc-grows-in-europe-and-targets-us-123395.html Allergy Therapeutics hopes to launch "exciting" grass pollen allergy vaccine in 2019 https://www.proactiveinvestors.com.au/companies/news/304675/allergy-therapeutics-hopes-to-launch-exciting-grass-pollen-allergy-vaccine-in-2019-4675.html Thu, 18 Feb 2016 15:38:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304675/allergy-therapeutics-hopes-to-launch-exciting-grass-pollen-allergy-vaccine-in-2019-4675.html Allergy Therapeutics enrols 250 for grass pollen allergy trial https://www.proactiveinvestors.com.au/companies/news/122669/allergy-therapeutics-enrols-250-for-grass-pollen-allergy-trial-122669.html Thu, 18 Feb 2016 07:34:00 +1100 https://www.proactiveinvestors.com.au/companies/news/122669/allergy-therapeutics-enrols-250-for-grass-pollen-allergy-trial-122669.html Allergy Therapeutics boss says the firm is outperforming its competitors https://www.proactiveinvestors.com.au/companies/news/304547/allergy-therapeutics-boss-says-the-firm-is-outperforming-its-competitors-4547.html Wed, 13 Jan 2016 16:03:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304547/allergy-therapeutics-boss-says-the-firm-is-outperforming-its-competitors-4547.html Allergy Therapeutics posts double digit revenue growth https://www.proactiveinvestors.com.au/companies/news/121255/allergy-therapeutics-posts-double-digit-revenue-growth-121255.html Wed, 13 Jan 2016 07:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/121255/allergy-therapeutics-posts-double-digit-revenue-growth-121255.html Allergy Therapeutics could gain from rival's problems, says Panmure https://www.proactiveinvestors.com.au/companies/news/120585/allergy-therapeutics-could-gain-from-rival-s-problems-says-panmure-120585.html Thu, 17 Dec 2015 10:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/120585/allergy-therapeutics-could-gain-from-rival-s-problems-says-panmure-120585.html Allergy Therapeutics starts enrolment for US grass allergy trial https://www.proactiveinvestors.com.au/companies/news/120099/allergy-therapeutics-starts-enrolment-for-us-grass-allergy-trial-120099.html Mon, 07 Dec 2015 07:39:00 +1100 https://www.proactiveinvestors.com.au/companies/news/120099/allergy-therapeutics-starts-enrolment-for-us-grass-allergy-trial-120099.html Allergy Therapeutics ready to begin phase II trials on birch pollen innoculation https://www.proactiveinvestors.com.au/companies/news/119815/allergy-therapeutics-ready-to-begin-phase-ii-trials-on-birch-pollen-innoculation-119815.html Mon, 30 Nov 2015 07:57:00 +1100 https://www.proactiveinvestors.com.au/companies/news/119815/allergy-therapeutics-ready-to-begin-phase-ii-trials-on-birch-pollen-innoculation-119815.html Allergy Therapeutics medical chief on Polyvac Peanut potential https://www.proactiveinvestors.com.au/companies/news/304376/allergy-therapeutics-medical-chief-on-polyvac-peanut-potential-4376.html Wed, 18 Nov 2015 13:31:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304376/allergy-therapeutics-medical-chief-on-polyvac-peanut-potential-4376.html Allergy Therapeutics to add to pipeline following US$18mln funding https://www.proactiveinvestors.com.au/companies/news/119319/allergy-therapeutics-to-add-to-pipeline-following-us18mln-funding-119319.html Tue, 17 Nov 2015 15:47:00 +1100 https://www.proactiveinvestors.com.au/companies/news/119319/allergy-therapeutics-to-add-to-pipeline-following-us18mln-funding-119319.html Allergy Therapeutics raising £12mln for market step change https://www.proactiveinvestors.com.au/companies/news/119263/allergy-therapeutics-raising-12mln-for-market-step-change-119263.html Tue, 17 Nov 2015 13:47:00 +1100 https://www.proactiveinvestors.com.au/companies/news/119263/allergy-therapeutics-raising-12mln-for-market-step-change-119263.html Allergy Therapeutics to present data at World Vaccine Congress https://www.proactiveinvestors.com.au/companies/news/117056/allergy-therapeutics-to-present-data-at-world-vaccine-congress-117056.html Wed, 04 Nov 2015 08:52:00 +1100 https://www.proactiveinvestors.com.au/companies/news/117056/allergy-therapeutics-to-present-data-at-world-vaccine-congress-117056.html Allergy Therapeutics has major opportunity in US, says Stifel https://www.proactiveinvestors.com.au/companies/news/116158/allergy-therapeutics-has-major-opportunity-in-us-says-stifel-116158.html Tue, 13 Oct 2015 09:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/116158/allergy-therapeutics-has-major-opportunity-in-us-says-stifel-116158.html Panmure upbeat on Allergy Therapeutics after Q3 results https://www.proactiveinvestors.com.au/companies/news/111369/panmure-upbeat-on-allergy-therapeutics-after-q3-results-111369.html Thu, 01 Oct 2015 13:51:00 +1000 https://www.proactiveinvestors.com.au/companies/news/111369/panmure-upbeat-on-allergy-therapeutics-after-q3-results-111369.html Allergy Therapeutics to sniff out more M&A deals, says CEO https://www.proactiveinvestors.com.au/companies/news/304162/allergy-therapeutics-to-sniff-out-more-ma-deals-says-ceo-4162.html Mon, 21 Sep 2015 14:14:00 +1000 https://www.proactiveinvestors.com.au/companies/news/304162/allergy-therapeutics-to-sniff-out-more-ma-deals-says-ceo-4162.html Allergy Therapeutics chief expects company to be more active in M&A https://www.proactiveinvestors.com.au/companies/news/110974/allergy-therapeutics-chief-expects-company-to-be-more-active-in-ma-110974.html Mon, 21 Sep 2015 13:36:00 +1000 https://www.proactiveinvestors.com.au/companies/news/110974/allergy-therapeutics-chief-expects-company-to-be-more-active-in-ma-110974.html UPDATE: Allergy Therapeutics rises after better than expected results https://www.proactiveinvestors.com.au/companies/news/110966/update-allergy-therapeutics-rises-after-better-than-expected-results-110966.html Mon, 21 Sep 2015 10:51:00 +1000 https://www.proactiveinvestors.com.au/companies/news/110966/update-allergy-therapeutics-rises-after-better-than-expected-results-110966.html Allergy Therapeutics recruits first patient to dosing trial https://www.proactiveinvestors.com.au/companies/news/110409/allergy-therapeutics-recruits-first-patient-to-dosing-trial-110409.html Tue, 01 Sep 2015 07:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/110409/allergy-therapeutics-recruits-first-patient-to-dosing-trial-110409.html UPDATE - Allergy Therapeutics team publish research https://www.proactiveinvestors.com.au/companies/news/109804/update-allergy-therapeutics-team-publish-research-109804.html Mon, 10 Aug 2015 14:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/109804/update-allergy-therapeutics-team-publish-research-109804.html Allergy Therapeutics' sales beat forecasts https://www.proactiveinvestors.com.au/companies/news/109268/allergy-therapeutics-sales-beat-forecasts-109268.html Thu, 23 Jul 2015 11:21:00 +1000 https://www.proactiveinvestors.com.au/companies/news/109268/allergy-therapeutics-sales-beat-forecasts-109268.html ROUNDUP - Allergy Therapeutics shares rise as it reveals positive results from dust mite study https://www.proactiveinvestors.com.au/companies/news/108697/roundup-allergy-therapeutics-shares-rise-as-it-reveals-positive-results-from-dust-mite-study-108697.html Mon, 06 Jul 2015 13:04:00 +1000 https://www.proactiveinvestors.com.au/companies/news/108697/roundup-allergy-therapeutics-shares-rise-as-it-reveals-positive-results-from-dust-mite-study-108697.html Allergy Therapeutics director on novel dust mite allergy treatment https://www.proactiveinvestors.com.au/companies/news/303912/allergy-therapeutics-director-on-novel-dust-mite-allergy-treatment-3912.html Mon, 06 Jul 2015 12:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/303912/allergy-therapeutics-director-on-novel-dust-mite-allergy-treatment-3912.html Allergy Therapeutics to present dust mite data at key conference https://www.proactiveinvestors.com.au/companies/news/108614/allergy-therapeutics-to-present-dust-mite-data-at-key-conference-108614.html Thu, 02 Jul 2015 06:42:00 +1000 https://www.proactiveinvestors.com.au/companies/news/108614/allergy-therapeutics-to-present-dust-mite-data-at-key-conference-108614.html Allergy Therapeutics’ momentum renewed with US programme kick-start https://www.proactiveinvestors.com.au/companies/news/108400/allergy-therapeutics-momentum-renewed-with-us-programme-kick-start-108400.html Thu, 25 Jun 2015 12:29:00 +1000 https://www.proactiveinvestors.com.au/companies/news/108400/allergy-therapeutics-momentum-renewed-with-us-programme-kick-start-108400.html Allergy Therapeutics resumes development of allergy treatment in US https://www.proactiveinvestors.com.au/companies/news/108365/allergy-therapeutics-resumes-development-of-allergy-treatment-in-us-108365.html Thu, 25 Jun 2015 06:29:00 +1000 https://www.proactiveinvestors.com.au/companies/news/108365/allergy-therapeutics-resumes-development-of-allergy-treatment-in-us-108365.html Allergy Therapeutics builds European presence with Alerpharma deal https://www.proactiveinvestors.com.au/companies/news/107776/allergy-therapeutics-builds-european-presence-with-alerpharma-deal-107776.html Fri, 05 Jun 2015 12:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/107776/allergy-therapeutics-builds-european-presence-with-alerpharma-deal-107776.html Allergy Therapeutics sees US breakthrough as route to global success https://www.proactiveinvestors.com.au/companies/news/67805/allergy-therapeutics-sees-us-breakthrough-as-route-to-global-success-79032.html “We are at an inflexion point,” says chief executive Manuel Llobet. “The immunotherapy business today is basically European, but it is going to become global very soon.”

]]>
Tue, 07 Apr 2015 13:03:00 +1000 https://www.proactiveinvestors.com.au/companies/news/67805/allergy-therapeutics-sees-us-breakthrough-as-route-to-global-success-79032.html
Allergy Therapeutics chief explains importance of £20mln fundraise https://www.proactiveinvestors.com.au/companies/news/303179/allergy-therapeutics-chief-explains-importance-of-20mln-fundraise-3179.html Tue, 31 Mar 2015 09:18:00 +1100 https://www.proactiveinvestors.com.au/companies/news/303179/allergy-therapeutics-chief-explains-importance-of-20mln-fundraise-3179.html Allergy Therapeutics' £20mln fundraise gets green light from investors https://www.proactiveinvestors.com.au/companies/news/67610/allergy-therapeutics-20mln-fundraise-gets-green-light-from-investors-78819.html Mon, 30 Mar 2015 11:17:00 +1100 https://www.proactiveinvestors.com.au/companies/news/67610/allergy-therapeutics-20mln-fundraise-gets-green-light-from-investors-78819.html Allergy Therapeutics shares jump after US vaccine approval https://www.proactiveinvestors.com.au/companies/news/38831/allergy-therapeutics-shares-jump-after-us-vaccine-approval-46400.html Fri, 03 Aug 2012 09:15:00 +1000 https://www.proactiveinvestors.com.au/companies/news/38831/allergy-therapeutics-shares-jump-after-us-vaccine-approval-46400.html Allergy Therapeutics’ prospects “are improving”, says broker Panmure https://www.proactiveinvestors.com.au/companies/news/28762/allergy-therapeutics-prospects-are-improving-says-broker-panmure-34374.html Fri, 14 Oct 2011 10:51:00 +1100 https://www.proactiveinvestors.com.au/companies/news/28762/allergy-therapeutics-prospects-are-improving-says-broker-panmure-34374.html Allergy Therapeutics announces £22 million fundraising, Weinstein family of Chile to become largest shareholder https://www.proactiveinvestors.com.au/companies/news/4447/allergy-therapeutics-announces-22-million-fundraising-weinstein-family-of-chile-to-become-largest-shareholder--6117.html Fri, 12 Jun 2009 08:29:00 +1000 https://www.proactiveinvestors.com.au/companies/news/4447/allergy-therapeutics-announces-22-million-fundraising-weinstein-family-of-chile-to-become-largest-shareholder--6117.html Allergy Therapeutics boosted by FDA approval for Phase III trial https://www.proactiveinvestors.com.au/companies/news/465/allergy-therapeutics-boosted-by-fda-approval-for-phase-iii-trial-0783.html
The FDA also accepted the company's plans to conduct a single pivotal Phase III trial for registration - expected to start in March, 2007.

This follows a recent announcement that the company had begun dosing patients in its Phase III trial for Pollinex Quattro Grass - the first ever global allergy vaccine trial.

Pollinex Quattro is an ultra-short course vaccine requiring only four shots over three weeks in contrast to existing vaccine treatments which normally require between 16 and 50 injections taken under specialist supervision. Allergy Therapeutics has three Pollinex Quattro allergy vaccines in clinical development: Grass, Tree and Ragweed.

Over 150m people are estimated to suffer from hay fever - a market currently worth an estimated US$12 billion per annum.


CEO Keith Carter, added:

"We recently announced the first patient dosed in our pivotal Phase III Pollinex Quattro Grass trial. Today's announcement confirms that we are in the enviable position of having two allergy vaccines in late stage of clinical development. We have just opened a new manufacturing facility in the UK, part of a significant investment programme to ramp up production capacity ahead of the expected registration of these products next year.

"We believe these products are best in class, and will provide an important new treatment option for the millions of moderate to sever allergy sufferers."
]]>
Wed, 31 Jan 2007 08:23:00 +1100 https://www.proactiveinvestors.com.au/companies/news/465/allergy-therapeutics-boosted-by-fda-approval-for-phase-iii-trial-0783.html